malignant melanoma
TRANSCRIPT
![Page 1: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/1.jpg)
The Farmer with the Skin LesionLogan Carr
![Page 2: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/2.jpg)
History• CC: “Changing brown spot on hand”• HPI: PM is a 74 y/o Caucasian male with a fair
complexion. He has had a pigmented area on his left hand for 4-5 years, then he recently, within the last 2 years, noticed that a dark spot in the middle of the pigmented area was enlarging. He also reports a new white crust. He denies any bleeding, ulceration, itching or pain involved with the area. He has a history of sun exposure at an early age.
![Page 3: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/3.jpg)
History Cont’d.• PMH: GERD, Hyperlipidemia• Meds: omeprazole, pravastatin• PSH: multiple BCC/SCC removed from back and
shoulders, bilateral cataract removal.• FMH: Sister has a hx of melanoma 20 years ago on
her inner thigh. • SH: Worked on a farm as a child and young adult
and then as a delivery man later in life. Had a great deal of sun exposure throughout his life.• ROS: No headache, fever, weight changes, SOB,
hemoptysis, CP, Palpitations, N/V/D/C, abd. pain, or swelling in his extremities.
![Page 4: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/4.jpg)
Physical Exam• Vitals: BP: 132/88 P: 73 RR: 15 T: 98 F • HEENT: head normocephalic, EOMI, PERRL, nares
patent and nonerythematous, no neck LAD, no thyromegaly• Heart: normal S1/S1, no murmurs• Lungs: CTA b/l, no WRR• GI: NBS all quadrants, no bruits, tympanic, with no
pain on palpation, no masses• MS: normal strength • Neuro: CN 2-12 intact
![Page 5: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/5.jpg)
Physical Exam Cont’d.• Skin: There is a roughly 3 cm x 1 cm patch on the
dorsal aspect of his left fifth metacarpophalangeal joint. It has irregular borders and color variation.• It also has a 1cm x 1cm papule that was slightly
darker. This area was previously biopsied.• Patient also has other nevi over chest, shoulders,
and arms. • No lymphadenopathy in epitrochlear or axillary area
on the left side. • Labs: CBC done preoperatively was completely
within normal range
![Page 6: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/6.jpg)
The patient’s skin lesion
White Crust
1cm
3cm
Central area of darkening
Fifth digit
Fourth digit
Fifth MCP joint
![Page 7: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/7.jpg)
Differential Diagnosis
• Malignant melanoma : Changing, darkening, large• Atypical Nevi: suspicious moles• Pigmented Basal Cell Carcinoma: pink, pearly,
rolled edges, crateriform • Seborrheic Keratosis: stuck on, verrucous or wart
like• Solar Lentigo (liver spots): light brown macules
![Page 8: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/8.jpg)
Most likely diagnosis?
![Page 9: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/9.jpg)
Clinical Diagnosis of MelanomaSpec Sens ABCDE mnemonic and description
72% 57%A- Asymmetry= a line through the middle will not create matching halves
71% 57% B- Border Irregularity= scalloped or notched edges
59% 65% C- Color Variation= varied shades of brown, tan or black and even red, white and blue at later stages
63% 90% D- Diameter >6mm
90% 84% E- Evolving= size, shape, surface (bleeding) and symptoms (itching, pain)
![Page 10: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/10.jpg)
The patient’s skin lesion
Border irregularity
Asymmetry
Color variation
Diameter
Elevation
Evolving
![Page 11: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/11.jpg)
Risk factors for Melanoma• A changing mole (most important risk factor) • Atypical/dysplastic nevi (particularly >5–10).• Large numbers of common nevi (>100).• A history of melanoma.• Sun sensitivity/history of excessive sun exposure or sunburn.• Melanoma in a first-degree relative.• Prior non-melanoma skin cancer (basal cell and squamous cell
carcinoma).• Male gender.• Age >50• A fair-skin phenotype (blue/green eyes, blond or red hair, light
complexion, sun sensitivity) and the occurrence of blistering sunburns in childhood and adolescence
![Page 12: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/12.jpg)
Types of Melanoma
1. Superficial Spreading type: 70 % of all melanomas, occur in sun exposed areas. Arise from preexisting nevi, grow in radial growth pattern during early stages
2. Nodular: 15-25 % of all melanomas, occur in old men, resemble a blood blister, arise de novo and are usually deep at time of diagnosis
3. Lentigo maligna: 5-10% of all melanomas, occur only in sun exposed areas, have convoluted borders, and a prolonged radial growth phase
4. Acral lentiginous: 2-8% of all melanomas, more common in darker skin patients, occur in non sun exposed areas, on sole of foot, palm and beneath nail beds, very aggressive.
![Page 13: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/13.jpg)
Epidemiology
In 2007 only in the US:• Approximately 110,000 people were
diagnosed with melanoma• 8110 people died of metastatic disease• Incidence has plateaued since the 90s•Most common cancer in women of 25-29 y/o•Median age of diagnosis is 53 y/o
![Page 14: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/14.jpg)
Path report of punch biopsyHistological Type Malignant melanoma
Maximum thickness 0.95 mm (Breslow 3)
Anatomic level Invades reticular dermis (Clark 4)
Mitotic index <1 mitosis/mm2
Size 0.2mm in depth and diameter
![Page 15: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/15.jpg)
Margins During Excision
Tumor Thickness
WHO
In situ 5mm
≤1mm 1cm
1-2mm 1cm
2-4mm 2cm
>4mm 2cm
Currently Recommended Excision Margins for Primary Melanoma
Clark Breslow Thickness
Historic Measurements of Invasion for staging and prognosis
![Page 16: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/16.jpg)
Overview of Treatment Algorithm
Radiation and Chemotherapy
![Page 17: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/17.jpg)
Technetium Lymphoscintogram • Purpose: To help localize the region of lymphatic
drainage and more specifically the sentinel node.• Solution: 454 uCi of Technetium Tc 99m Sulfur
Colloid • Procedure: The solution was divided into 4
aloquots and injected subdermally in 4 locations around the melanoma lesion. The area was massaged to help distribute the solution in the tissue. Do scintigraph to determine lymph node locations:• Adverse effects: small radiation exposure,
anaphylactic reactions, rash, and hypotension
![Page 18: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/18.jpg)
Sentinel Lymph Node Biopsy
1. Inject lympho serum blue: ½ cc in all four quadrants
2. Initial background reading of axilla through skin: 200
3. Sentinel lymph node was located and dissected out with geiger counter assistance.
4. Ex vivo reading was 1300.5. New background noise was 130 (goal < 10% of
ex vivo).
![Page 19: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/19.jpg)
Final Path Report
Histological Type Malignant melanoma
Thickness 1.02 mm
Mitotic index 5 mitosis/mm2
Clark level IV (invades reticular dermis)
Ulceration none
SLNB 2 nodes both negative for cancer
![Page 20: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/20.jpg)
Staging
Histological Type Malignant melanoma
Thickness 1.02 mm
Ulceration none
SLNB 2 nodes both negative for cancer
Metastasis N/A
![Page 21: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/21.jpg)
Staging
PATHOLOGIC STAGING T N0 Tis N0IA T1a N0IB T1b N0 T2a N0IIA T2b N0 T3a N0IIB T3b N0 T4a N0IIC T4b N0IIIA T1-4a N1a T1-4a N2aIIIB T1-4b N1a T1-4b N2a T1-4a N1b T1-4a N2b T1-4a N2cIIIC T1-4b N1b T1-4b N2b T1-4b N2c any T N3IV any T any N
Histological Type Malignant melanoma
Thickness 1.02 mm
Ulceration none
SLNB 2 nodes both negative for cancer
Metastasis N/A
T2a N0
![Page 22: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/22.jpg)
Overview of Treatment Algorithm
See NCCN guidelines for complicated algorithm and follow-up recommendations (handout)
![Page 23: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/23.jpg)
Sentinel node biopsy or nodal observation in melanoma.• Study design: Randomized controlled trial with 5 year
endpoint• Primary site: Dr. DL Morton at the John Wayne Cancer
Institute at Saint John’s Health Center Santa Monica, CA• Before SLNB: observation until clinically detectable
lymph nodes or CLND from the beginning. • Conclusions: Staging of primary melanomas according to
SLNB helps to prolong survival by identifying patients who had micro-metastasis and needed complete lymph node dissection immediately.
![Page 24: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/24.jpg)
References1. Thomas L. Semiological value of ABCDE criteria in the diagnosis of
cutaneous pigmented tumors. Dermatology. 1998;197:11–17.2. Sabel MS. Chapter 44. Oncology. In: Doherty GM, ed. CURRENT
Diagnosis & Treatment: Surgery. 13th ed. New York: McGraw-Hill; 2011. http://www.accessmedicine.com.proxy.cc.uic.edu/ content.aspx?aID=5316764. Accessed November 14, 2011.
3. Usatine RP. Chapter 165. Melanoma. In: Usatine RP, Smith MA, Chumley H, Mayeaux, Jr. E, Tysinger J, eds. The Color Atlas of Family Medicine. New York: McGraw-Hill; 2011. http://www.accessmedicine.com.proxy.cc.uic.edu/content.aspx?aID=8207960. Accessed November 12, 2011.
4. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 351:998, 2004
![Page 25: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/25.jpg)
References
5. Lens MB, et al. Excision margins in the treatment of primary cutaneous melanoma: A systematic review of randomized controlled trials comparing narrow versus wide excision. Arch Surg. 2002;137:1101–1105.
6. Cole P, Heller L, Bullocks J, Hollier LH, Stal S. Chapter 16. The Skin and Subcutaneous Tissue. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE, eds. Schwartz's Principles of Surgery. 9th ed. New York: McGraw-Hill; 2011. http://www.accessmedicine.com.proxy.cc.uic.edu/content.aspx?aID=5019723. Accessed November 15, 2011.
7. Morton DL et al: Sentinel node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307.
![Page 26: Malignant Melanoma](https://reader033.vdocument.in/reader033/viewer/2022061108/544e4a7db1af9f2b638b4fa4/html5/thumbnails/26.jpg)